SCIENTIFIC REPORTS

OPEN

Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy

Atsuhiko Kanda^{1,2}, Kousuke Noda^{1,2}, Wataru Saito² & Susumu Ishida^{1,2}

Received: 28 September 2015

Accepted: 09 November 2015

Published: 09 December 2015

Vascular endothelial growth factor (VEGF)-A-driven angiogenesis contributes to various disorders including cancer and proliferative diabetic retinopathy (PDR). Among several VEGF-A blockers clinically used is aflibercept, a chimeric VEGFR1/VEGFR2-based decoy receptor fused to the Fc fragment of IgG1 (*i.e.*, VEGFR1/VEGFR2-Fc). Here, we revealed a novel anti-angiogenic function for aflibercept beyond its antagonism against VEGF family members. Immunoprecipitation and mass spectrometry analyses identified galectin-1 as an aflibercept-interacting protein. Biolayer interferometry revealed aflibercept binding to galectin-1 with higher affinity than VEGFR1-Fc and VEGFR2-Fc, which was abolished by deglycosylation of aflibercept with peptide-*N*-glycosidase F. Retinal *LGALS1/Galectin-1* mRNA expression was enhanced *in vitro* by hypoxic stimulation and *in vivo* by induction of diseases including diabetes. Galectin-1 immunoreactivity co-localized with VEGFR2 in neovascular tissues surgically excised from human eyes with PDR. Compared with non-diabetic controls, intravitreal galectin-1 protein levels were elevated in PDR eyes, showing no correlation with increased VEGF-A levels. Preoperative injection of bevacizumab, a monoclonal antibody to VEGF-A, reduced the VEGF-A, but not galectin-1, levels. Galectin-1 application to human retinal microvascular endothelial cells up-regulated VEGFR2 phosphorylation, which was eliminated by aflibercept. Our present findings demonstrated the neutralizing efficacy of aflibercept against galectin-1, an angiogenic factor associated with PDR independently of VEGF-A.

Angiogenesis is the formation of new blood vessels from a pre-existing vascular bed and usually occurs during embryogenesis, wound healing, and organ regeneration. This biological phenomenon, executed by vascular endothelial cells that constitute the inner lining of blood vessels, comprises multistep programs including matrix degradation, cell proliferation/migration, tube formation and matrix deposition, and eventually results in the formation of a new microvasculature. Numerous studies have been conducted to show that vascular endothelial growth factor (VEGF)-A is a major endothelial cell mitogen among a rich variety of pro-angiogenic molecules reported so far.

Tumor growth and metastasis depend on angiogenesis activated by pathological signaling from tumor cells¹. Activation of the VEGF-A-VEGFR2 (the Flk-1/KDR receptor) axis initiates a network of multiple signaling processes, which has been implicated as a key pathway required for pathological angiogenesis in cancer². Pathological angiogenesis is also a hallmark of various ischemic and inflammatory disorders³. In the field of ophthalmology, abnormal angiogenesis driven by VEGF-A was shown to cause vision-threatening retinal and choroidal diseases including proliferative diabetic retinopathy (PDR) and age-related macular degeneration (AMD)^{4,5}. PDR, the advanced stage of diabetic retinopathy, is characterized by fibrovascular proliferation, in which fibrovascular tissue is formed by the extension of retinal new vessels into the vitreous cavity, resulting in severe complications such as vitreous hemorrhage and tractional retinal detachment. Wet type of AMD is complicated by choroidal neovascularization (CNV) involving the macula, the photoreceptor-dense central area of the retina, and thus causing central vision loss and blindness with submacular hemorrhage and exudative retinal detachment. Several anti-VEGF-A agents, successfully developed, have so far been widely used for the treatment of cancer and eye diseases^{6–11}.

Aflibercept, also known as VEGF-Trap, is currently used for the treatment of various ocular abnormalities as Eylea (*i.e.*, CNV seen in wet AMD¹⁰ and pathological myopia¹², and macular edema seen in branch and central

¹Laboratory of Ocular Cell Biology and Visual Science, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, 060-8638, Japan. ²Department of Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan. Correspondence and requests for materials should be addressed to A.K. (email: kanda@med.hokudai.ac.jp) or S. I. (email: ishidasu@med.hokudai.ac.jp)

Figure 1. Molecular binding of aflibercept with galectin-1. (A) Human RPE cell extracts were applied with aflibercept- or normal IgG-immobilized protein G beads. The eluted proteins were separated by SDS-PAGE and visualized with silver staining. A single protein band around 14 kDa was detected (arrow). (B) Co-IP of human RPE cell extracts using aflibercept was performed, followed by SDS-PAGE and immunoblot (IB) analyses for galectin-1. (C) Co-transfection and Co-IP. V5-tagged *VEGF-Trap_{R1R2}* expression plasmids were co-transfected into HEK293T cells with Myc-tagged *Galectin-1/LGALS1* expression constructs. IP was performed with anti-Myc antibody followed by detection with anti-V5 antibody.

retinal vein occlusions^{13–15} and diabetic retinopathy⁹) and metastatic colorectal cancer as Zaltrap¹¹. Aflibercept is a pharmacologically engineered glycoprotein consisting of the ligand-binding elements of human VEGFR1 (Ig domain 2) and VEGFR2 (Ig domain 3), fused to the Fc portion of human IgG1¹⁶. This unique protein structure allows aflibercept to bind VEGF-A with higher affinity than other VEGF-A blockers and to interact with other VEGF family members such as VEGF-B and placental growth factor¹⁷; however, its biological potential has not been completely unveiled. Due to its structure artificially designed and thus naturally non-existing, we hypothesized a possibility that aflibercept may interact with an unexpected protein so as to modify its function. Here we report the first evidence that aflibercept binds and neutralizes a pro-angiogenic molecule outside of the VEGF family, showing an additional anti-angiogenic capability beyond its originally prepared anti-VEGF function.

Results

Identification of aflibercept-interacting proteins. To isolate aflibercept-interacting proteins from the human retinal pigment epithelium (RPE) cell line, we first performed immunoprecipitation (IP) using aflibercept and RPE cell extracts. The bound proteins were eluted, analyzed by electrophoresis, and detected by silver staining (Fig. 1A). A significant protein band corresponding to approximately 14 kDa was observed in the immunoprecipitates with aflibercept as compared to those with normal human IgG and PBS with aflibercept (Fig. 1A), suggesting a specific interaction between this protein and aflibercept.

Identified protein	Gene name	Molecular mass (Da)	No. of peptides	Score	Sequence coverage (%)	Calculated pI value	p value	Accession number
Galectin-1	LGALS1	14,716	11	184	77	5.34	<0.05	P09382

Table 1. Summary of identified aflibercept-interacting protein.

Figure 2. Binding affinity of aflibercept with galectin-1. (A) Kinetic analysis of galectin-1 binding with aflibercept using the BLItz biolayer interferometry system. Sensorgrams obtained using aflibercept-loaded biosensors incubated with different concentrations of galectin-1 as analytes. Dotted lines indicate the start of the binding (left) and the dissociation (right) phase. (B) Sensorgrams obtained using biosensors loaded with aflibercept with (dotted line) or without (solid line) deglycosylation (+ PNGase F or Denatured PNGase F, respectively) and incubated with galectin-1 at the concentration of 50 µg/ml. (C,D) Sensorgrams obtained using biosensors loaded with VEGFR1-Fc (C) or VEGFR2-Fc (D) and incubated with different concentrations of galectin-1.

This protein band (Fig. 1A) was excised from the gel and trypsinized. The resulting peptides were analyzed by mass spectrometry (MS) and searched with the Mascot program. As a result, one protein, galectin-1, was identified (Table 1). In addition, we performed these IP and MS procedures using rat retinal capillary endothelial cells (TR-iBRB2) so as to obtain the same results (Supplementary Fig. S1).

Molecular binding of aflibercept with galectin-1. To validate the IP and MS results (Fig. 1A and Table 1), we performed co-IP experiments using RPE cell extracts as an input sample with aflibercept and immunoblotting with anti-galectin-1 antibody. In accordance with the IP/MS data (Fig. 1A), aflibercept demonstrated the precipitation of galectin-1 protein from the RPE cell extracts, while the input RPE cell extracts used as a positive control showed an immunoreactive band of the predicted size (Fig. 1B).

To further verify the molecular interaction between aflibercept and galectin-1, co-IP experiments followed by immunoblot analyses were performed with transfected HEK293T cells using antibodies against V5- or Myc-tag. We subcloned *VEGF-Trap_{R1R2}* and *LGALS1* cDNAs into expression vectors containing V5 and Myc, respectively, and co-transfected both of these constructs into HEK293T cells. IP with anti-Myc antibody from the co-transfected cell extracts demonstrated that galectin-1 could pull down aflibercept (Fig. 1C), further confirming the protein interaction between aflibercept and galectin-1.

Binding affinity of aflibercept with galectin-1. To determine the affinity of the interaction between aflibercept and galectin-1, and to investigate the influence of stoichiometry on the interaction, sensorgrams were collected for galectin-1 using biosensors loaded with aflibercept. Analysis for the sensorgrams of Fig. 2A yielded

Sensor	K_D	k_a (1/Ms)	k_d (1/s)
Aflibercept	23.68 nM	$1.57E+4 \pm 0.03E+4$	$3.71E-4 \pm 0.32E-4$
PNase F-treated aflibercept	867.8 nM	$6.12E+3 \pm 0.28E+3$	$5.31E-3 \pm 0.22E-3$
VEGFR1-Fc	3032 nM	$2.04E+3 \pm 0.34E+3$	$6.18E-3 \pm 0.27E-3$
VEGFR2-Fc	334.3 nM	$9.51E+3 \pm 0.34E+3$	$3.18E-3 \pm 0.15E-3$

Table 2. Equilibrium dissociation constant (K_D) and kinetic constants (k_a and k_d).

a dissociation constant (K_D) of 23.68 nM for the interaction of galectin-1 with aflibercept (Table 2). Recently, galectin-1 has been shown to interact with *N*-glycans on Ig domains 3, 4 and 7 of VEGFR2¹⁸, one of which (Ig domain 3) is utilized as the VEGFR2 region of aflibercept¹⁶. To test a requirement of *N*-glycosylation of aflibercept for its interaction with galectin-1, we incubated aflibercept with peptide:*N*-glycosidase F (PNGase F) to cleave *N*-linked glycans. PNGase F treated-aflibercept showed a significantly lower binding affinity than aflibercept treated with denatured PNGase F (Fig. 2B), and yielded a K_D of 868.7 nM for the interaction of deglycosylated aflibercept with galectin-1 (Table 2 and Supplementary Fig. S2). These results suggest that galectin-1 recognizes and binds the *N*-glycans on the VEGFR2 region of aflibercept.

Next, in order to verify the significance of the VEGFR2 region to interact with galectin-1, we measured and compared the binding affinity of galectin-1 with VEGFR1-Fc (Fig. 2C) and VEGFR2-Fc (Fig. 2D). K_D values for the interaction of galectin-1 with VEGFR1-Fc and VEGFR2-Fc were 3032 nM and 334.3 nM, respectively (Table 2), showing a considerably lower affinity of VEGFR1-Fc than VEGFR2-Fc with galectin-1, in consistency with the recent report¹⁸. The data also confirmed the robust binding of aflibercept to galectin-1 with higher affinity compared to VEGFR1-Fc and VEGFR2-Fc.

Induction of retinal *Galectin-1/LGALS1* mRNA. Galectin-1 was reported to be expressed physiologically and pathologically in various regions of the mammalian retina, including the RPE, external limiting membrane, and outer plexiform layer^{19,20}. Hypoxia-inducible factor (HIF)-1 α protein, an oxygen-sensitive subunit of HIF-1 that is a master factor for cellular response to hypoxia, regulates *LGALS1/Galectin-1* mRNA in cancer cells²¹. To investigate the effect of hypoxic stimulation on *LGALS1* mRNA expression in human retinal cell lines, we checked *LGALS1* mRNA levels using real-time PCR. Hypoxia led to significant upregulation of *LGALS1* gene expression in various human cell lines including RPE (Fig. 3A; 8 h, fold change = 1.19; 24 h, fold change = 1.31), Y79 (Fig. 3B; 8 h, fold change = 0.92; 24 h, fold change = 1.67), and human retinal microvascular endothelial cells (HRMEC) (Fig. 3C; 8 h, fold change = 1.05; 24 h, fold change = 1.21).

Next, we checked the induction of murine *Lgals1* mRNA in various eye disease models; streptozotocin-induced diabetes, laser-induced CNV, and endotoxin-induced uveitis (EIU); all of which were shown to involve the activation of the HIF-1 pathway^{22–24}. *In vivo*, *Lgals1* mRNA levels were significantly upregulated in the retina (diabetes at months 1, 2 and 6; EIU at day 1) and the RPE-choroid complex (CNV at day 4), compared to controls (Fig. 3D; Diabetes-1M, fold change = 0.89; Diabetes-2M, fold change = 12.83; Diabetes-6M, fold change = 38.62. Fig. 3E; CNV, fold change = 2.06. Fig. 3F; EIU, fold change = 1.41).

Localization of galectin-1 in PDR fibrovascular tissues. To examine the tissue localization and expression of galectin-1, we carried out immunofluorescence and RT-PCR for fibrovascular tissues surgically excised from human PDR eyes. Double-staining experiments demonstrated co-localization of galectin-1 with CD31 (Fig. 4A–C) and GFAP (Fig. 4D–F), showing its ubiquitous distribution to neovascular endothelial cells and glial cells, respectively, both of which were the major cellular components in the fibrovascular tissues. Importantly, galectin-1 co-localized with VEGFR2 in the new vessels (Fig. 4G–I), suggesting the VEGFR2-mediated pathogenic role of galectin-1 in PDR as well as in tumor angiogenesis^{18,21}. We also confirmed mRNA expression of *LGALS1* in healthy adult retinas and the fibrovascular tissues (Fig. 4J).

Elevation of galectin-1 protein levels in PDR vitreous fluids. To investigate the production of galectin-1 in PDR eyes, we performed ELISA experiments to measure galectin-1 protein levels in vitreous fluids aspirated from PDR and non-diabetic control eyes with idiopathic epiretinal membrane (ERM) and macular hole (MH). We divided PDR patients into two groups with or without intravitreal bevacizumab (anti-VEGF-A monoclonal antibody) injection 2–3 days before surgery (bevacizumab-treated, 8 eyes; non-treated, 15 eyes). Galectin-1 levels were significantly elevated in the vitreous fluids of PDR eyes (Bevacizumab –, 8.46 ± 0.82 ng/ml; Bevacizumab +, 11.12 ± 1.48 ng/ml) compared with controls (2.82 ± 0.65 ng/ml) (Fig. 5A). Notably, there was no significant difference in galectin-1 levels between eyes with or without bevacizumab pretreatment, in stark contrast to the following data on VEGF-A.

Intraocular levels of VEGF-A, a key molecule responsible for angiogenesis, were shown to be increased in PDR eyes⁴. To examine the relationship between galectin-1 and VEGF-A, we checked VEGF-A protein levels in the PDR vitreous samples. VEGF-A protein levels in PDR eyes receiving no bevacizumab (0.948 ± 0.230 ng/ml) were significantly higher than those of bevacizumab-treated PDR eyes (0.041 ± 0.021 ng/ml) and controls (0.023 ± 0.019 ng/ml) (Fig. 5B). Interestingly, in PDR eyes without bevacizumab pretreatment, intravitreal protein levels of VEGF-A were not correlated with those of galectin-1 (Fig. 5C), suggesting that these two molecules were independently regulated.

Suppression of galectin-1-mediated VEGFR2 activation by aflibercept. Galectin-1 binding to VEGFR2 has recently been shown to activate the VEGFR2 signaling pathway^{18,25}. To determine the effect of

Figure 3. Induction of retinal *Galectin-1/LGALS1* mRNA *in vitro* and *in vivo*. (A–C) *LGALS1* mRNA expression in hypoxia (1% O₂)-stimulated cell culture using RPE (A), Y79 (B) and HRMEC (C). (D–F) *Lgals1* mRNA expression in retinal tissues from disease model mice with streptozotocin-induced diabetes (D), CNV (E) and EIU (F). * $p < 0.05$, ** $p < 0.01$ (n = 6 per group).

aflibercept on galectin-1-mediated VEGFR2 activation, we evaluated the relative phosphorylation of VEGFR2 *in vitro* by ELISA. Administration of galectin-1 as well as VEGF-A to HRMEC significantly increased VEGFR2 phosphorylation compared with controls (Galectin-1, fold change = 3.45; VEGF-A, fold change = 6.80), both of which were remarkably suppressed by aflibercept (Galectin-1 + aflibercept, fold change = 0.95; VEGF-A + aflibercept, fold change = 1.13; Control + aflibercept, fold change = 0.98) (Fig. 5D).

Phosphorylation of VEGFR2 in vascular endothelial cells causes its growth signal activation, largely via the second messenger phospholipase C- γ and subsequent mitogen-activated protein kinase cascades, leading to cell proliferation and angiogenesis^{2,3}. To investigate the effect of aflibercept on galectin-1-induced angiogenesis, we performed proliferation assay using HRMEC. In accordance with a previous report using human umbilical vein endothelial cells²⁵, administration of galectin-1 as well as VEGF-A to HRMEC significantly stimulated cell proliferation compared with controls (Galectin-1, fold change = 2.77; VEGF-A, fold change = 4.09), both of which were notably inhibited by pretreatment with aflibercept (Galectin-1 + aflibercept, fold change = 0.96; VEGF-A +

Figure 4. Localization of galectin-1 in human PDR fibrovascular tissues. (A–C) Double labeling of galectin-1 (green), CD31 (red) and DAPI (blue) in PDR fibrovascular tissues. (D–F) Double labeling of galectin-1 (green), GFAP (red) and DAPI (blue) in PDR fibrovascular tissues. (G–I) Double labeling of galectin-1 (green), VEGFR2 (red) and DAPI (blue) in PDR fibrovascular tissues. Scale bar = 30 μm . (J) End-point PCR analysis. Gene expression of *LGALS1* in healthy human retinas and PDR fibrovascular tissues.

aflibercept, fold change = 1.46; Control + aflibercept, fold change = 0.97) (Fig. 5E). These findings demonstrated the capability of aflibercept for blocking the angiogenic function of galectin-1 as a VEGFR2 ligand.

Discussion

In various physiological and pathological conditions, cell-surface glycans are remodeled by the sequential enzymatic action of glycosyltransferases and glycosidases. Glycans can regulate molecular interactions that involve both homotypic and heterotypic bindings, and have multiple principal biological functions in protein maturation/turnover, cell adhesion/trafficking, and receptor binding/activation^{26,27}. In the present study, aflibercept, the VEGFR1/VEGFR2-fused glycan-modified protein, was shown to interact with galectin-1 (Fig. 1), and its binding

Figure 5. Elevation of galectin-1 protein levels in human PDR vitreous fluids and suppression of galectin-1-mediated VEGFR2 activation by aflibercept in HRMEC. (A) Protein levels of galectin-1 in PDR eyes with ($n = 8$) or without ($n = 15$) bevacizumab pretreatment and in control (ERM + MH) eyes ($n = 12$). Black symbols indicate individual samples in each group with a bar showing the average. $**p < 0.01$. (B) Protein levels of VEGF-A in PDR eyes with or without bevacizumab pretreatment and in control eyes. (C) No correlation ($p = 0.137$, $r^2 = 0.150$) between galectin-1 and VEGF-A in PDR eyes without bevacizumab pretreatment. (D) VEGFR2 phosphorylation induced by galectin-1 as well as VEGF-A, both of which were significantly suppressed by aflibercept. Data are shown as relative values compared to PBS ($n = 5$ per group). (E) HRMEC proliferation induced by galectin-1 and VEGF-A, both of which were significantly suppressed by aflibercept. Data are shown as relative values compared to PBS ($n = 8$ per group).

ability to galectin-1 was abolished by deglycosylation with a specific *N*-glycosidase (Fig. 2). There are some possible explanations for the currently observed higher affinity of galectin-1 with aflibercept than with VEGFR2. Firstly, different host cells used for generating these recombinant proteins, *i.e.*, CHO (rodent ovary) cells for aflibercept and HEK293 (human kidney) cells for VEGFR2-Fc, are likely to individually change carbohydrate structures on

their Ig domain 3. Another possibility is that protein surface accessibilities may be altered because VEGFR2-Fc used here is comprised of the entire extracellular domain of VEGFR2 (Met1-Glu764) in contrast to the limited region (Ig domain 3, Leu105-Lys205) contained in aflibercept.

Under pathological conditions such as hypoxia responsible for various ocular disorders, *LGALS1* (*Lgals1*) mRNA expression levels were upregulated in human retinal cell lines and the murine retinal tissues (Fig. 3). Furthermore, galectin-1 was expressed and co-localized with VEGFR2 in neovascular endothelial cells in fibrovascular tissues surgically excised from eyes of patients with PDR (Fig. 4). Importantly, vitreous aspirates from PDR eyes showed protein levels of galectin-1 higher than those from controls, which was not correlated with VEGF-A levels also increased in PDR eyes (Fig. 5). Preoperative treatment with an anti-VEGF-A antibody bavituzumab failed to reduce galectin-1 levels in PDR eyes, whereas aflibercept administration to human retinal endothelial cells significantly suppressed galectin-1-stimulated VEGFR2 activation (Fig. 5). Our current data provided a novel insight into anti-VEGF-A therapeutic strategies in terms that aflibercept traps galectin-1, a VEGF-A-independent VEGFR2 ligand associated with the pathogenesis of PDR as well as various retinal disease models.

Galectins, a galactoside-binding lectin protein family, have an evolutionally conserved carbohydrate-recognition domain capable of interacting with β -galactosides, particularly *N*-acetylglucosamine-containing glycans. Galectins bind to cell surface glycol-conjugated proteins or lipids, and modify cellular functions without having specific receptors like cytokines²⁸. Various biological functions of galectins include homeostasis, apoptosis, and pathological conditions such as inflammation, cancer and diabetes^{29,30}. Several transcription factors such as HIF-1 α , nuclear factor- κ B and activator protein-1 are known to regulate *LGALS1/Galectin-1* gene expression^{21,31}. Galectin-1 plays multifaceted roles in cell adhesion/proliferation, angiogenesis and immunosuppression, targeting not only a variety of cancer cells, but also vascular endothelial cells and regulatory T cells^{21,32}. Suppression of *LGALS1* expression by RNA interference was shown to increase sensitivity to anti-cancer drugs³³. In mammalian eyes, galectin-1 was found in various regions including the RPE, photoreceptor inner segment, external limiting membrane, outer and inner plexiform layers, nerve fiber layer, and choroidal vessels^{19,20}. In human specimens, galectin-1 expression co-localized to the migrated RPE cells in fibrous tissues surgically removed from eyes with proliferative vitreoretinopathy, and *in vitro* stimulation by hepatocyte growth factor caused a migratory RPE phenotype via elevation of galectin-1 levels, mimicking the pathogenesis of proliferative vitreoretinopathy¹⁹.

Recently, galectin-1 was reported to play a crucial role in promoting angiogenesis in anti-VEGF-A refractory tumors¹⁸. Galectin-1 was shown to interact with the *N*-glycans on Ig domains 3, 4 and 7 of VEGFR2, causing increased phosphorylation of VEGFR2 and activation of its downstream signaling pathways in endothelial cells. Anti-VEGF-A refractory tumors enhanced galectin-1 secretion together with its increased binding to neovascular endothelial cells due to altered glycosylation patterns (i.e., decreased α 2,6-linked sialic acid) on VEGFR2, leading to galectin-1-driven angiogenesis and tumor progression. More recently, we have shown a significant increase in sialylated *N*-glycans in eyes of patients with PDR and a relative decrease in α 2,6-linked sialic acid in glucose-stimulated human retinal endothelial cells³⁴. In concert with the currently observed elevation of galectin-1 in PDR eyes (Fig. 5), these recent reports suggest a potential role of altered *N*-glycan profiles in the angiogenic activity in PDR as well as cancer.

Intravitreal injection of VEGF-A blockers is a first-line therapy for several ocular disorders such as wet AMD and diabetic macular edema; however, the anti-VEGF-A strategy is not necessarily effective for all patients. Despite the excellent results of numerous prospective clinical trials, 10 to 30% of patients have been shown to be non-responders for anti-VEGF-A drugs^{35,36}. Although the retrospective design and the small number of cases constitute limitations, several reports have suggested the efficacy of switching to aflibercept in patients with wet AMD who were primarily or secondarily refractory to other anti-VEGF-A agents^{37–39}. In a prospective head-to-head clinical trial, aflibercept has been shown to be more effective in improving vision than other two blockers for patients with diabetic macular edema at relatively low levels of initial visual acuity⁴⁰.

Several biological properties of aflibercept may explain the theoretical rationale of these efficacious results suggesting its superiority. Aflibercept binds to VEGF-A with much higher affinity than other VEGF-A blockers, and a low potential for immunogenicity due to its human-based sequence allows for a slow clearance by conferring a long half-life¹⁶. Moreover, aflibercept is distinguished from other anti-VEGF-A drugs by its ability to bind other VEGF family members such as placental growth factor¹⁷, which was also strongly correlated with angiogenic stages of diabetic retinopathy⁴¹. Lastly, our present findings revealed an additional anti-angiogenic role of aflibercept in neutralizing galectin-1, a non-VEGF family angiogenic factor associated with human diabetic retinopathy.

Methods

Cell lines and animals. Human RPE (hTERT-RPE1), retinoblastoma (Y79) and HEK293T cells were obtained from American Type Culture Collection (Manassas, VA). Rat retinal endothelial cells (TR-iBRB2) were provided from Fact Inc. (Sendai, Japan)⁴². HRMEC, CS-C medium, a growth medium optimized for HRMEC, and CultureBoost were purchased from Cell Systems (Kirkland, WA). For hypoxic exposure, cells were cultured in a gas mixture composed of 1% O₂, 5% CO₂, and 94% N₂. For cell stimulation, after being serum-deprived, cells were treated with 10 μ g/ml galectin-1 or 5 ng/ml VEGF-A (R&D systems, Minneapolis, MN) at 37 °C for 10 min with or without 7.5 μ g/ml aflibercept (Santen Pharmaceutical Co. Ltd, Osaka, Japan) to measure VEGFR2 phosphorylation. For cell proliferation, cells were treated in the same way but for incubation time of 48 h.

C57BL/6J mice were obtained from CLEA Japan (Tokyo, Japan). All animal experiments were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and approved by the Ethics Review Committee for Animal Experimentation of Hokkaido University. Procedures for murine models of streptozotocin-induced diabetes, laser-induced CNV and EIU were described in our previous reports^{43–45}.

Immunoprecipitation. Cells were homogenized in TBS containing 1% NP-40 and protease inhibitors (Roche Applied Science, Indianapolis, IN). After pre-incubation of samples with Protein G beads (Life Technologies, Carlsbad, CA) for 1 h at 4 °C, antibodies were added and left overnight at 4 °C with gentle mixing. The beads were washed three times with lysis buffer, and suspended in SDS sample buffer.

Nanoscale liquid chromatography with tandem mass spectrometry (nanoLC-MS/MS). Immunoprecipitated samples were resolved on a 4–15% Mini-PROTEAN TGX gels (Bio-Rad, Hercules, CA) and stained using a Mass silver stain kit (Wako Pure Chemical Industries, Osaka, Japan). Gel slippage was reduced by 100 mM of dithiothreitol and alkylated by 100 mM iodoacetamide. After washing, gels were incubated with trypsin overnight at 30 °C. Recovered peptides were desalted by Ziptip c18 (Millipore, Billerica, MA). Samples were analyzed by nanoLC-MS/MS systems (DiNa HPLC system, KYA Technologies, Tokyo, Japan; QSTAR XL, Life Technologies). Mass data acquisitions were piloted by Mascot software for matching proteins in the NCBI database.

Immunoblot analyses. Cell extracts were lysed in SDS buffer and a protease inhibitor cocktail (Roche Applied Science). Proteins were resolved by 10% SDS-PAGE (polyacrylamide gel electrophoresis) and transferred to PVDF (polyvinylidene difluoride) membrane (Millipore) by electroblotting. Membranes were blocked in TBS containing 5% skim milk, and incubated with the following primary antibodies: anti-Galectin-1 (Abcam, Cambridge, MA) antibody, anti-V5 antibody (Life Technologies) and anti-Myc antibody (Medical & Biological Laboratories, Nagoya, Japan). The secondary antibodies for chemoluminescence detection were peroxidase-conjugated anti-mouse or anti-rabbit IgGs (Jackson ImmunoResearch Laboratories, West Grove, PA). Signal was obtained by enhanced chemoluminescence (Western Lightning Ultra, Perkin Elmer, Waltham, MA).

Plasmid constructions. Human *LGALS1/Galectin-1* cDNA (GenBank No. NM_002305) was obtained from DNASU Plasmid Repository (Tempe, AZ) and subcloned into pCMV-Tag 3B vector (Agilent Technologies) with Myc tag and pGEX4T-2 vector (GE Healthcare, Piscataway, NJ) for glutathione S-transferase (GST) fusion. *VEGF-Trap_{R1R2}* (corresponding to aflibercept) cDNA¹⁶ was generated as a synthetic gene by IDT (Coralville, IA), and subcloned into the pcDNA6.2/V5-DEST vector (Life Technologies) with V5 tag. The empty pcDNA6.2/V5-DEST vector was used as a Mock transfection control. The GST-fused galectin-1 protein was expressed in an *Escherichia coli* strain Rosetta-gami 2 (DE3) (Novagen, Madison, WI), and purified through binding to Glutathione Sepharose (GE Healthcare). All constructs were sequence-verified before use.

Biolayer interferometry. Protein binding affinities were quantified by biolayer interferometry using the BLITZ instrument (ForteBio, Menlo Park, CA). Aflibercept, VEGFR1-Fc and VEGFR2-Fc (Sino Biological Inc., Beijing, China) proteins were immobilized on Protein A-coated biosensors, and equilibrated in buffer to establish a stable baseline as sensors, then dipped into various concentrations of GST-galectin-1 as analytes. All protein-binding experiments were done in PBS. Control values, measured using empty (no protein-loaded) sensors, were subtracted from experimental values before data processing. Preliminary binding experiments with GST protein using empty sensors and aflibercept-loaded sensors and with GST-galectin-1 using normal human IgG-loaded sensors yielded similar almost zero values indicating no specific binding (data not shown). For deglycosylation, aflibercept was incubated with PNGase F (New England Biolabs, Ipswich, MA) according to the manufacturer's instructions. As a negative control, PNGase F was inactivated by heat denaturation at 100 °C for 10 min. The equilibrium dissociation constant (K_D) together with association (k_a) and dissociation (k_d) rate constants were calculated using BLITZ Pro software.

RT-PCR and real-time PCR. Total RNA isolation and reverse transcription were performed from cells using SuperPrep Cell Lysis & RT Kit for qPCR (TOYOBO, Tokyo, Japan) and from tissues using TRIzol (Life Technologies) and GoScrip Reverse Transcriptase (Promega, Madison, WI) with oligo dT(20) primers, as previously described⁴⁴. The following primers for genes were used: human *LGALS1* (galectin-1; forward 5'-CGC TAA GAG CTT CGT GCT GAA C-3', reverse 5'-CAC ACC TCT GCA ACA CTT CCA G-3'), human *ACTB* (β -actin; forward 5'-CTG GAA CGG TGA AGG TGA CA-3', reverse 5'-AAG GGA CTT CCT GTA ACA ATG CA-3'), mouse *Lgals1* (forward 5'-TCC CCG AAC TTT GAG ACA TTC-3', reverse 5'-GTC TCA GGA ATC TCT TCG CTT C-3'), probe 5'-ACC AGA CCA CAG GCC ATG ATT GAA-3'), and mouse *Gapdh* (glyceraldehyde-3-phosphate dehydrogenase; forward 5'-AGG TCG GTG TGA ACG GAT TTG-3', reverse 5'-TGT AGA CCA TGT AGT TGA GGT CA-3').

Human surgical samples. Vitreous fluids were collected from 23 eyes of 23 patients (11 males and 12 females, average age = 55.0 ± 2.1 years) with PDR. Undiluted vitreous samples were collected at the start of pars plana vitrectomy using the transconjunctival sutureless vitrectomy system (23G or 25G) and were frozen rapidly at -80 °C. Control vitreous samples were obtained from 12 eyes of 12 age-matched, non-diabetic patients (4 males and 8 females, average age = 60.4 ± 1.9 years) with idiopathic macular diseases including ERM and MH. During surgery, 5 fibrovascular tissues were excised from PDR eyes and used for immunohistochemistry, and additional 3 fibrovascular tissues were processed for gene expression analyses. This study was conducted in accordance with the tenets of the Declaration of Helsinki and after receiving approval from the institutional review board of Hokkaido University Hospital. All patients gave written informed consent after our explanation of the purpose and procedures of this study. We obtained 3 human (healthy adults) retina cDNAs as a kind gift from Dr. Anand Swaroop (National Eye Institute, Bethesda, MD).

Immunofluorescence microscopy. Paraffin sections of fibrovascular tissues were deparaffinized and hydrated through exposure with xylene and graded alcohols followed by water. As a pretreatment, microwave-based

antigen retrieval was performed in 10 mM citrate buffer (pH 6). Sections were probed with the following primary antibodies: anti-Galectin-1 (Abcam), anti-VEGFR2 (R&D systems, Minneapolis, MN), anti-CD31 (DAKO, Tokyo, Japan), and anti-GFAP (glial fibrillary acidic protein; Leica, Exton, PA) antibodies. The secondary antibodies for fluorescent detection were AlexaFluor 488 and 546 (Life Technologies). Nuclei were counterstained with DAPI (diamidino-2-phenylindole), and sections were visualized under a Bioevo microscope (Keyence, Tokyo, Japan).

ELISA. The protein levels of galectin-1 and VEGF-A in vitreous fluids and those of VEGFR2 and phosphorylated VEGFR2 *in vitro* were determined with human Galectin-1, VEGF-A, VEGFR2 and Phospho-VEGFR2 ELISA kits (R&D systems) per the manufacturer's instructions. Levels of phosphorylated VEGFR2 were normalized by VEGFR2 protein concentrations. The optical density was determined using a micro plate reader (Sunrise, TECAN, Männedorf, Switzerland).

Cell proliferation assay. RealTime-Glo MT cell viability assay (Promega) was used to quantify viable cells, according to the manufacturer's instructions. The luminescent signal was determined using Infinite 200 PRO (TECAN).

Statistical analyses. All results were expressed as mean $\pm$ SEM. The values were processed for statistical analyses (Student's t-test and Spearman rank correlation). Differences between the means were considered statistically significant when the *P* values were < 0.05 .

References

- Folkman, J. Tumor angiogenesis: therapeutic implications. *N Engl J Med* **285**, 1182–1186 (1971).
- Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *J Clin Oncol* **23**, 1011–1027 (2005).
- Hoeben, A. *et al.* Vascular endothelial growth factor and angiogenesis. *Pharmacol Rev* **56**, 549–580 (2004).
- Adamis, A. P. *et al.* Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. *Am J Ophthalmol* **118**, 445–450 (1994).
- Ferrara, N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. *Nat Med* **16**, 1107–1111 (2010).
- Rosenfeld, P. J. *et al.* Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med* **355**, 1419–1431 (2006).
- Hurwitz, H. *et al.* Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* **350**, 2335–2342 (2004).
- Ng, E. W. *et al.* Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. *Nat Rev Drug Discov* **5**, 123–132 (2006).
- Do, D. V. *et al.* The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. *Ophthalmology* **118**, 1819–1826 (2011).
- Heier, J. S. *et al.* Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. *Ophthalmology* **119**, 2537–2548 (2012).
- Tabernero, J. *et al.* Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. *Eur J Cancer* **50**, 320–331 (2014).
- Ikuno, Y. *et al.* Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. *Ophthalmology* **122**, 1220–1227 (2015).
- Ogura, Y. *et al.* Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. *Am J Ophthalmol* **158**, 1032–1038 (2014).
- Brown, D. M. *et al.* Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPENICUS study. *Am J Ophthalmol* **155**, 429–437 e427 (2013).
- Campochiaro, P. A. *et al.* Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. *Ophthalmology* **122**, 538–544 (2015).
- Holash, J. *et al.* VEGF-Trap: a VEGF blocker with potent antitumor effects. *Proc Natl Acad Sci USA* **99**, 11393–11398 (2002).
- Papadopoulos, N. *et al.* Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. *Angiogenesis* **15**, 171–185 (2012).
- Croci, D. O. *et al.* Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. *Cell* **156**, 744–758 (2014).
- Alge, C. S. *et al.* Galectin-1 influences migration of retinal pigment epithelial cells. *Invest Ophthalmol Vis Sci* **47**, 415–426 (2006).
- Uehara, F., Ohba, N. & Ozawa, M. Isolation and characterization of galectins in the mammalian retina. *Invest Ophthalmol Vis Sci* **42**, 2164–2172 (2001).
- Zhao, X. Y. *et al.* Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. *Carcinogenesis* **31**, 1367–1375 (2010).
- Kondo, T. & Kahn, C. R. Altered insulin signaling in retinal tissue in diabetic states. *J Biol Chem* **279**, 37997–38006 (2004).
- Lin, M. *et al.* Impacts of hypoxia-inducible factor-1 knockout in the retinal pigment epithelium on choroidal neovascularization. *Invest Ophthalmol Vis Sci* **53**, 6197–6206 (2012).
- Poulaki, V. *et al.* Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. *FASEB J* **21**, 2113–2123 (2007).
- D'Haene, N. *et al.* VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis. *PLoS One* **8**, e67029 (2013).
- Marth, J. D. & Grewal, P. K. Mammalian glycosylation in immunity. *Nat Rev Immunol* **8**, 874–887 (2008).
- Ohtsubo, K. & Marth, J. D. Glycosylation in cellular mechanisms of health and disease. *Cell* **126**, 855–867 (2006).
- Astorgues-Xerri, L. *et al.* Unraveling galectin-1 as a novel therapeutic target for cancer. *Cancer Treat Rev* **40**, 307–319 (2014).
- Pugliese, G. *et al.* The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. *Diabetes* **49**, 1249–1257 (2000).
- Thijssen, V. L. *et al.* Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. *Proc Natl Acad Sci USA* **103**, 15975–15980 (2006).
- Toscano, M. A. *et al.* Nuclear factor (NF)-kappaB controls expression of the immunoregulatory glycan-binding protein galectin-1. *Mol Immunol* **48**, 1940–1949 (2011).
- Thijssen, V. L., Poirier, F., Baum, L. G. & Griffioen, A. W. Galectins in the tumor endothelium: opportunities for combined cancer therapy. *Blood* **110**, 2819–2827 (2007).
- Mathieu, V. *et al.* Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. *J Invest Dermatol* **127**, 2399–2410 (2007).

34. Inafuku, S. *et al.* Alteration of N-Glycan Profiles in Diabetic Retinopathy. *Invest Ophthalmol Vis Sci* **56**, 5316–5322 (2015).
35. Lux, A., Llacer, H., Heussen, F. M. & Jousseaume, A. M. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. *Br J Ophthalmol* **91**, 1318–1322 (2007).
36. Otsuji, T. *et al.* Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). *Clin Ophthalmol* **7**, 1487–1490 (2013).
37. Chang, A. A. *et al.* Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. *Ophthalmology* **121**, 188–192 (2014).
38. Batioglu, F., Demirel, S., Ozmert, E., Abdullayev, A. & Bilici, S. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. *BMC Ophthalmol* **15**, 40 (2015).
39. Kumar, N. *et al.* Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. *Retina* **33**, 1605–1612 (2013).
40. Diabetic Retinopathy Clinical Research, N. *et al.* Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med* **372**, 1193–1203 (2015).
41. Ando, R. *et al.* Aqueous humour levels of placental growth factor in diabetic retinopathy. *Acta Ophthalmol* **92**, e245–246 (2014).
42. Hosoya, K. *et al.* Conditionally immortalized retinal capillary endothelial cell lines (TR-iBRB) expressing differentiated endothelial cell functions derived from a transgenic rat. *Exp Eye Res* **72**, 163–172 (2001).
43. Satofuka, S. *et al.* (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. *Diabetes* **58**, 1625–1633 (2009).
44. Kanda, A., Noda, K., Oike, Y. & Ishida, S. Angiopoietin-like protein 2 mediates endotoxin-induced acute inflammation in the eye. *Lab Invest* **92**, 1553–1563 (2012).
45. Dong, Z. *et al.* Specific inhibition of serine/arginine-rich protein kinase attenuates choroidal neovascularization. *Mol Vis* **19**, 536–543 (2013).

Acknowledgements

We thank Anand Swaroop (National Eye Institute) for sharing human retinal samples, and Ikuyo Hirose, Shiho Yoshida, Erdal Tan Ishizuka, Miyuki Murata, and Yoko Dong (Hokkaido University) for technical assistance. This work was supported in part by the Takeda Science Foundation (to A.K.).

Author Contributions

A.K. and S.I. designed the study, A.K., K.N. and W.S. performed the experiments, and A.K. and S.I. analyzed the data and wrote the paper. All authors approved the final version submitted for publication.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Kanda, A. *et al.* Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. *Sci. Rep.* **5**, 17946; doi: 10.1038/srep17946 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>